Vertex Pharmaceuticals Incorporated VRTX stock has declined 23.6% in the past six months, mainly due to recent pipeline setbacks. In August 2025, Vertex’s phase II study on the oral formulation of ...

Vertex Pharmaceuticals Incorporated VRTX reported second-quarter 2024 results on Aug 1. Adjusted loss per share of $12.83 was wider than the Zacks Consensus Estimate of a loss of $11.50. The ...

Vertex Pharmaceuticals (NasdaqGS:VRTX) is reassessing its pain management program after disappointing FDA label discussions ...

Vertex Pharmaceuticals (NASDAQ:VRTX) is scheduled to announce its earnings on Monday, May 5, 2025. For event-driven traders, understanding historical stock performance around earnings releases can be ...

Vertex Pharmaceuticals has just seen its price target move from a previously unspecified level to a new, undisclosed figure.

In mid-January 2026, Bernstein upgraded Vertex Pharmaceuticals to Outperform and UBS initiated coverage with a Buy rating, ...